09
Apr

What’s All the Hubbub, Bub? GSK Withdrawals Leucovorin Calcium – Again!

A few months before the end of 2025, the FDA requested that Glaxo Smith-Kline (GSK) revise its approved labeling by submitting a supplemental application to its Wellcovorin (leucovorin calcium) to include an indication for cerebral folate deficiency (CFD), a rare disorder. This came after Secretary Kennedy’s thus far unsuccessful hunt for the cause of autism. […]

Read More
01
Apr
First Generic Approvals - Lachman Blog

First NME Approved through Commissioners National Priority Voucher (CNPV) Program

Today, FDA approved Lilly’s GLP-1 oral tablet as the first approval of a new molecular entity (NME) through the CNPV program. The FDA says the drug Foundayo (orforglipron), “was approved 50 days after the NDA was filed and 294 days before the application’s PDUFA date of January 20, 2027”. According to the FDA (here), commissioner […]

Read More
31
Mar
FDA’s Quarterly Monthly Listing of Potential Signals of Serious Adverse Events and Risks

FDA’s Quarterly Monthly Listing of Potential Signals of Serious Adverse Events and Risks

Every 3 months, FDA updates its New Safety Information or Potential Signals of Serious Risks Identified from the FDA Adverse Event Monitoring System listings (here) to include newly identified potential serious risks that FDA is investigating. The FDA wants to emphasize that “[T]he appearance of a drug or biological product on a quarterly report does […]

Read More
25
Mar
FDA Requires New B6 Deficiency Warning on Parkinsons Drug

FDA Requires New B6 Deficiency Warning on Parkinsons Drug

On March 20, 2026, the FDA issued a Warning (here) notifying healthcare providers and patients that Carbidopa/Levodopa drug products can cause vitamin B6 deficiency and vitamin B6 deficiency-associated seizures.  The warning instructs healthcare providers to monitor B6 levels in their patients taking the combination therapy, and recommends taking a baseline B6 level at the beginning of treatment.  B6 […]

Read More
20
Mar
FDA Q&A Guidance for Endotoxin and Pyrogen Testing Arrived Yesterday

FDA Q&A Guidance for Endotoxin and Pyrogen Testing Arrived Yesterday

While endotoxin and pyrogen testing might not be the sexiest of topics, they are extremely important topics for creating a safe sterile product. I believe that FDA has made your job easier by their recent publication of the guidance titled Pyrogen and Endotoxins Testing ‒ Questions and Answers (Edition 2) yesterday (here). It contains a […]

Read More
10
Mar
FDA Approves New Indication for Leucovorin Calcium - Lachman Blog

FDA Approves New Indication for Leucovorin Calcium

The FDA announced (here) that it has approved leucovorin calcium for “cerebral folate deficiency (CFD), a neurological condition that affects folate (a vitamin essential for brain health) transport into the brain. Individuals with cerebral folate deficiency have been observed to have developmental delays with autistic features (e.g., challenges with social communication, sensory processing, and repetitive […]

Read More
02
Mar
SUPAC Guidances to Get an Update - Lachman Blog

SUPAC Guidances to Get an Update?

In today’s Federal Notice pre-publication page (here), the FDA is requesting information and comment from industry and the public on whether it’s time to update the series of Scale-Up and Post Approval Changes (SUPAC) guidance documents. The SUPAC documents were issued between 1995 and 1997 (with the exception of SUPAC Manufacturing Equipment Addendum, which was […]

Read More
25
Feb
Access 2026 Meeting More from Day One - Lachman Blog

Access 2026 Meeting: More from Day One

The Association of Accessible Medicines (AAM) continued Day 1 with a discussion of what’s happening on Capitol Hill and how we can be working to position industry priorities with policymakers to make the most positive impact on patient access. The session was conducted as a fireside chat hosted by Mark Ratner, Senior Vice President, Government Affairs, […]

Read More
11
Feb
iPledge-Blogimage-LachmanBlog

FDA Approved Modifications to iPLEDGE REMS Program for Isotretinoin Products

On February 9, 2026, the FDA approved modifications to the Risk Evaluation and Mitigation Strategy (REMS) program for the safe use of isotretinoin. The REMS program has undergone various changes since its initial inception in 2005. The shared program (brand and generic applicants) is designed to mitigate the risk of fetal toxicity from isotretinoin. The current […]

Read More
30
Jan
Prescription medication container being held in hand

Is Labeling of Prescriptions Drugs About to Get More Crowded?

Senator Rick Scott of Florida introduced the Consumer Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings (Clear Labels Act), which “would require prescription drug labeling to disclose the original manufacturers of generic drugs and APIs, giving patients, providers, and regulators clear, upfront information about a drug’s origins.”  According to his website […]

Read More
1 … 3 4 5 … 35